甲强龙球旁注射治疗重症HSK的临床疗效分析  

The Clinical Efficacy of Methylprednisolone Sodium Succinate for Periocular Injection in the Treatment of Severe Herpes Simplex Keratitis

作　　者：孙珊珊 孙倬[1] 

机构地区：[1]常州市第三人民医院,江苏 常州

出　　处：《临床医学进展》2021年第9期3930-3935,共6页Advances in Clinical Medicine

摘　　要：目的:探究甲强龙治疗重症单纯疱疹病毒角膜炎(herpessimplex keratitis, HSK)的临床疗效。方法:一项回顾性病例分析研究。收集自2018年1月至2019年1月因重症HSK在我院眼科住院治疗的47例患者(47眼)的临床资料进行分析研究。按治疗方式随机分成两组:观察组(25眼)和对照组(22眼)。对照组:常规治疗,观察组:常规治疗基础上,联合甲强龙球旁注射。观察指标:治疗3周后的最佳矫正视力(The best corrected visual acuity, BCVA)和有效率;随访1年时复发率和BCVA。结果:治疗3周后,观察组BCVA明显优于对照组(P 0.05)。结论:球旁注射甲强龙可有效缩短重症HSK病程,对患者的视力改善效果显著,同时可明显提高治疗的有效率,值得临床推广应用。Purpose: To investigate the clinical efficacy of Methylprednisolone sodium succinate for periocular injection in the treatment of severe herpes simplex keratitis (HSK). Methods: A retrospective case analysis study. A cohort of 47 patients (47 eyes) with severe HSK recruited between January 2018 and January 2019 was randomly divided into two groups according to the treatment they received: observation group (25 eyes) and control group (22 eyes). The control group: conventional treatment;observation group: conventional treatment combined with periocular injection of methylprednisolone sodium succinate. The best corrected visual acuity (BCVA) and effective rate was recorded after 3 weeks of treatment. The recurrence rate and BCVA were recorded followed up at 1 year. Results: After 3 weeks of treatment, BCVA in the observation group was significantly better than that in the control group (P 0.05). Conclusion: Periocular injection of methylprednisolone sodium succinate can effectively shorten the course of HSK, significantly improve the visual acuity of patients, significantly increase the effective rate of treatment, and be worthy of clinical application.

关 键 词：单纯疱疹病毒性角膜炎 病毒性角膜基质炎 甲泼尼龙琥珀酸钠 

分 类 号：R47[医药卫生—护理学]